ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eisai and Swedish Orphan Biovitrum side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

EisaiSwedish Orphan Biovitrum
studies on the registry644137
open to participants now156
phase 3 studies under way35
reach primary completion within a year134
programswith a study of their own in two years67

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEisaiSwedish Orphan Biovitrum
Phase 1

Eisai: 2 of its 6 programs at phase 1

  1. E2511phase 1
  2. E1018phase 1
33%
00%
Phase 2

Eisai: 2 of its 6 programs at phase 2

  1. ledasorextonphase 2
  2. E6742phase 2
33%

Swedish Orphan Biovitrum: 1 of its 7 programs at phase 2

  1. XOI Low Dosephase 2
14%
Phase 300%

Swedish Orphan Biovitrum: 2 of its 7 programs at phase 3

  1. pacritinibphase 3
  2. AR882phase 3
29%
Approved, new studies

Eisai: 2 of its 6 programs at approved, new studies

  1. Donepezilapproved, new study
  2. filgotinib maleateapproved, new study
33%

Swedish Orphan Biovitrum: 4 of its 7 programs at approved, new studies

  1. efanesoctocog alfaapproved, new study
  2. pegcetacoplanapproved, new study
  3. avatrombopagapproved, new study
  4. Interleukin 1 Receptor Antagonist Proteinapproved, new study
57%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eisai2 readouts · 0 phase 3···

Eisai, Feb ’27: 1 program whose next study reaches primary completion

  1. ledasorextonphase 2 · Feb 14 · NCT07493265
····

Eisai, Jul ’27: 1 program whose next study reaches primary completion

  1. E1018phase 1 · Jul 22 · NCT06854042
···
Swedish Orphan Biovitrum4 readouts · 1 phase 3

Swedish Orphan Biovitrum, Nov ’26: 2 programs whose next study reaches primary completion

  1. AR882phase 3 · Nov 0 · NCT07116746
  2. XOI Low Dosephase 2 · Nov 0 · NCT07116746

Swedish Orphan Biovitrum, Dec ’26: 1 program whose next study reaches primary completion

  1. pacritinibphase 3 · Dec 30 · NCT06782373
··

Swedish Orphan Biovitrum, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Mar 0 · NCT06716814
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eisai

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Swedish Orphan Biovitrum

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionEisaiSwedish Orphan Biovitrum
Arthritis, Rheumatoidboth · compare here

Eisai in Arthritis, Rheumatoid: 1 program

  1. filgotinib maleateapproved, new study

Their studies: Eisai’s studies of Arthritis, Rheumatoid in search

Swedish Orphan Biovitrum in Arthritis, Rheumatoid: 1 program

  1. Interleukin 1 Receptor Antagonist Proteinapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Arthritis, Rheumatoid in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetEisaiSwedish Orphan Biovitrum
JAK2filgotinib maleaterulepacritinibrule
A target, or a pathogen for a vaccine, known for: Eisai 2 of 6 · Swedish Orphan Biovitrum 5 of 7 programs (7 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.